Healthcare provider profile · identity verified

Kyaw Min, M.D.

Allopathic & Osteopathic Physicians|Family Medicine · SAN JOSE, CA · NPI 1942604665

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Kyaw Min, M.D. received $111.73 in general payments during 2025 across 4 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 29.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Zenpep.

Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Zenpep by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$111.73

4 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$33.12	29.6%	1	2025
Dexcom, Inc.	Unresolved — no canonical attribution shown	$30.78	27.6%	1	2025
Aimmune Therapeutics, Inc.	Unresolved — no canonical attribution shown	$25.38	22.7%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$22.45	20.1%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$111.73	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$33.12	1	2025
Source payment records 2025-07-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.12 · Open Payments source
Dexcom G6 Transmitter Normalized: dexcom g6 transmitter	Medical Supply	Dexcom, Inc.	$30.78	1	2025
Source payment records 2025-11-20 · Dexcom, Inc. · $30.78 · Open Payments source
ZENPEP Normalized: zenpep	Drug	Aimmune Therapeutics, Inc.	$25.38	1	2025
Source payment records 2025-11-25 · Aimmune Therapeutics, Inc. · $25.38 · Open Payments source
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$22.45	1	2025
Source payment records 2025-08-11 · AstraZeneca Pharmaceuticals LP · $22.45 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	67	exact normalized	Medicare Part D
ZENPEP zenpep	2025	Zenpep	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	ZENPEP open payments reported associated product	CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927	Zenpep · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	64	11
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	67	17

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1592	295
Amlodipine Besylate	Amlodipine Besylate	1134	215
Furosemide	Furosemide	885	129
Tamsulosin Hcl	Tamsulosin Hcl	811	157
Eliquis	Apixaban	802	109
Gabapentin	Gabapentin	694	129
Losartan Potassium	Losartan Potassium	649	126
Levothyroxine Sodium	Levothyroxine Sodium	565	75
Pantoprazole Sodium	Pantoprazole Sodium	430	114
Metoprolol Tartrate	Metoprolol Tartrate	403	101
Metformin Hcl	Metformin Hcl	395	90
Donepezil Hcl	Donepezil Hcl	393	51
Memantine Hcl	Memantine Hcl	385	41
Famotidine	Famotidine	329	72
Metoprolol Succinate	Metoprolol Succinate	283	72
Carvedilol	Carvedilol	276	63
Mirtazapine	Mirtazapine	259	64
Jardiance	Empagliflozin	227	39
Quetiapine Fumarate	Quetiapine Fumarate	224	45
Escitalopram Oxalate	Escitalopram Oxalate	223	33
Simvastatin	Simvastatin	222	36
Clopidogrel	Clopidogrel Bisulfate	217	47
Finasteride	Finasteride	217	40
Trazodone Hcl	Trazodone Hcl	200	45
Risperidone	Risperidone	191	23
Allopurinol	Allopurinol	187	38
Divalproex Sodium	Divalproex Sodium	187	36
Levetiracetam	Levetiracetam	187	37
Lisinopril	Lisinopril	174	45
Omeprazole	Omeprazole	174	45
Xarelto	Rivaroxaban	170	26
Hydralazine Hcl	Hydralazine Hcl	164	39
Potassium Chloride	Potassium Chloride	163	37
Cephalexin	Cephalexin	157	94
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	157	51
Sertraline Hcl	Sertraline Hcl	151	25
Rosuvastatin Calcium	Rosuvastatin Calcium	147	31
Montelukast Sodium	Montelukast Sodium	144	17
Spironolactone	Spironolactone	142	28
Latanoprost	Latanoprost	140	32
Glipizide	Glipizide	134	27
Lactulose	Lactulose	131	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	130	65
Tradjenta	Linagliptin	129	20
Carbidopa-Levodopa	Carbidopa/Levodopa	128	24
Lantus	Insulin Glargine,hum.Rec.Anlog	126	33
Ondansetron Hcl	Ondansetron Hcl	126	54
Bumetanide	Bumetanide	125	25
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	120	72
Prednisone	Prednisone	116	56
Fluoxetine Hcl	Fluoxetine Hcl	107	13
Amiodarone Hcl	Amiodarone Hcl	106	34
Digoxin	Digoxin	102	13
Hydroxyzine Hcl	Hydroxyzine Hcl	100	24
Alendronate Sodium	Alendronate Sodium	89	22
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	87	15
Duloxetine Hcl	Duloxetine Hcl	83	16
Oxycodone Hcl	Oxycodone Hcl	80	27
Albuterol Sulfate Hfa	Albuterol Sulfate	78	38
Midodrine Hcl	Midodrine Hcl	78	35
Brimonidine Tartrate	Brimonidine Tartrate	74	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	74	16
Vascepa	Icosapent Ethyl	72	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	69	suppressed
Farxiga	Dapagliflozin Propanediol	67	17
Olanzapine	Olanzapine	66	15
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	65	64
Baclofen	Baclofen	65	29
Tramadol Hcl	Tramadol Hcl	65	26
Brilinta	Ticagrelor	64	11
Lamotrigine	Lamotrigine	64	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	59	15
Doxazosin Mesylate	Doxazosin Mesylate	58	15
Esomeprazole Magnesium	Esomeprazole Magnesium	58	12
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	56	29
Hydrocortisone	Hydrocortisone	56	28
Triamcinolone Acetonide	Triamcinolone Acetonide	56	15
Warfarin Sodium	Warfarin Sodium	53	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	52	20
Icosapent Ethyl	Icosapent Ethyl	51	12
Lacosamide	Lacosamide	51	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	50	32
Januvia	Sitagliptin Phosphate	50	suppressed
Paroxetine Hcl	Paroxetine Hcl	50	suppressed
Megestrol Acetate	Megestrol Acetate	49	31
Klayesta	Nystatin	46	17
Raloxifene Hcl	Raloxifene Hcl	45	suppressed
Trulicity	Dulaglutide	45	suppressed
Atenolol	Atenolol	44	suppressed
Fluticasone Propionate	Fluticasone Propionate	44	16
Lorazepam	Lorazepam	44	suppressed
Lovastatin	Lovastatin	44	suppressed
Azelastine Hcl	Azelastine Hcl	43	suppressed
Ingrezza	Valbenazine Tosylate	43	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	43	14
Doxycycline Hyclate	Doxycycline Hyclate	42	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	42	suppressed
Mupirocin	Mupirocin	42	26
Nystop	Nystatin	42	25
Pravastatin Sodium	Pravastatin Sodium	42	12
Insulin Lispro	Insulin Lispro	41	22
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	40	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	40	suppressed
Buspirone Hcl	Buspirone Hcl	39	11
Calcitriol	Calcitriol	39	suppressed
Cyclosporine	Cyclosporine	39	suppressed
Glimepiride	Glimepiride	38	16
Aripiprazole	Aripiprazole	37	11
Budesonide	Budesonide	37	suppressed
Citalopram Hbr	Citalopram Hydrobromide	37	suppressed
Diclofenac Sodium	Diclofenac Sodium	37	21
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	37	18
Terazosin Hcl	Terazosin Hcl	37	suppressed
Fenofibrate	Fenofibrate	36	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	36	12
Isosorbide Dinitrate	Isosorbide Dinitrate	36	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	36	suppressed
Clonazepam	Clonazepam	35	suppressed
Clonidine Hcl	Clonidine Hcl	35	16
Enoxaparin Sodium	Enoxaparin Sodium	35	11
Humalog	Insulin Lispro	35	13
Chlorhexidine Gluconate	Chlorhexidine Gluconate	34	11
Ketoconazole	Ketoconazole	34	16
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	34	15
Admelog	Insulin Lispro	33	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	33	suppressed
Timolol Maleate	Timolol Maleate	33	suppressed
Benztropine Mesylate	Benztropine Mesylate	31	suppressed
Dapagliflozin	Dapagliflozin Propanediol	30	14
Sodium Chloride	0.9 % Sodium Chloride	30	16
Creon	Lipase/Protease/Amylase	29	suppressed
Ezetimibe	Ezetimibe	29	12
Fiasp	Insulin Aspart (Niacinamide)	29	suppressed
Insulin Aspart Flexpen	Insulin Aspart	28	suppressed
Methimazole	Methimazole	28	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	28	suppressed
Xifaxan	Rifaximin	27	suppressed
Humulin N	Insulin Nph Human Isophane	26	suppressed
Meclizine Hcl	Meclizine Hcl	26	16
Methadone Hcl	Methadone Hcl	26	suppressed
Nitroglycerin	Nitroglycerin	26	19
Atropine Sulfate	Atropine Sulfate	25	suppressed
Divalproex Sodium Er	Divalproex Sodium	25	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	25	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	25	suppressed
Sevelamer Hcl	Sevelamer Hcl	25	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	25	suppressed
Azithromycin	Azithromycin	24	18
Benazepril Hcl	Benazepril Hcl	24	suppressed
Cefdinir	Cefdinir	24	18
Clotrimazole	Clotrimazole	24	suppressed
Ertapenem	Ertapenem Sodium	24	suppressed
Humalog Kwikpen U-100	Insulin Lispro	24	suppressed
Nuplazid	Pimavanserin Tartrate	24	suppressed
Restasis	Cyclosporine	24	suppressed
Rivastigmine	Rivastigmine	24	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	23	suppressed
Linzess	Linaclotide	23	suppressed
Permethrin	Permethrin	23	17
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	22	suppressed
Calcium Acetate	Calcium Acetate	22	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Konvomep	Omeprazole/Sodium Bicarbonate	22	suppressed
Novolin N	Insulin Nph Human Isophane	22	suppressed
Prazosin Hcl	Prazosin Hcl	22	suppressed
Procrit	Epoetin Alfa	22	suppressed
Carbamazepine	Carbamazepine	21	suppressed
Entresto	Sacubitril/Valsartan	21	14
Erythromycin	Erythromycin Base	21	19
Glipizide Er	Glipizide	21	suppressed
Humulin R	Insulin Regular, Human	21	suppressed
Memantine Hcl Er	Memantine Hcl	21	suppressed
Nystatin	Nystatin	21	15
Clobetasol Propionate	Clobetasol Propionate	20	suppressed
Ibuprofen	Ibuprofen	20	suppressed
Metformin Hcl Er	Metformin Hcl	20	suppressed
Novolin R Flexpen	Insulin Regular, Human	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Levofloxacin	Levofloxacin	19	15
Novolog	Insulin Aspart	19	suppressed
Amoxicillin	Amoxicillin	18	12
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Insulin Aspart	Insulin Aspart	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Ranolazine Er	Ranolazine	18	suppressed
Santyl	Collagenase Clostridium Hist.	18	11
Vyzulta	Latanoprostene Bunod	18	suppressed
Breyna	Budesonide/Formoterol Fumarate	17	suppressed
Colchicine	Colchicine	17	13
Dextrose 5%-0.45% Nacl	Dextrose 5 %-0.45 % Sod Chlord	17	13
Linezolid	Linezolid	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Semglee (Yfgn)	Insulin Glargine-Yfgn	17	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	11
Morphine Sulfate Er	Morphine Sulfate	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Novolin R	Insulin Regular, Human	15	suppressed
Ozempic	Semaglutide	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	14
Zenpep	Lipase/Protease/Amylase	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	14	suppressed
Lithium Carbonate	Lithium Carbonate	14	suppressed
Methotrexate	Methotrexate Sodium	14	suppressed
Metolazone	Metolazone	14	suppressed
Rivastigmine	Rivastigmine Tartrate	14	suppressed
Sps	Sodium Polystyrene Sulfon/Sorb	14	suppressed
Tacrolimus	Tacrolimus	14	suppressed
Valsartan	Valsartan	14	suppressed
Admelog Solostar	Insulin Lispro	13	suppressed
Albuterol Sulfate	Albuterol Sulfate	13	suppressed
Brinzolamide	Brinzolamide	13	suppressed
Clozapine	Clozapine	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Dexamethasone	Dexamethasone	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Neupro	Rotigotine	12	suppressed
Praluent Pen	Alirocumab	12	suppressed
Prednisolone Acetate	Prednisolone Acetate	12	suppressed
Acetylcysteine	Acetylcysteine	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	11	suppressed
Fosinopril Sodium	Fosinopril Sodium	11	suppressed
Glucagon Emergency Kit	Glucagon	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Lagevrio (Eua)	Molnupiravir	11	11
Letrozole	Letrozole	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Olanzapine Odt	Olanzapine	11	suppressed
Rifampin	Rifampin	11	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	11	suppressed
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	11	suppressed
Travoprost	Travoprost	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$111.73 · 4 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	CAPLYTA, Dexcom G6 Transmitter, FARXIGA, ZENPEP	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error